() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Search for: "preveceutical"

PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

July 9, 2019 PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has completed the second phase of its soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”), by successfully developing formulations for cannabis extract-infused Sol-gels (the “CBD Sol-gel Formulations”), where both the acid and neutral cannabis extract forms have been incorporated.
Read more

PreveCeutical Secures $300,000 Loan and Resignation of a Director

June 3, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has received a loan in the aggregate amount of $300,000 (the “Loan”) pursuant to a loan agreement with the Company’s Chairman and Chief Executive Officer, Mr. Stephen Van Deventer (the “Lender”).
Read more

PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that the Company’s research team at the University of Queensland has been granted the necessary approvals from a local hospital’s Human Ethics Committee to acquire and use human nasal mucosal tissue (mucosal membrane) for the final phase of the cannabinoid-based, soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”).
Read more
Get $50 in free trades.